Back to top

Why the Earnings Surprise Streak Could Continue for Enanta Pharmaceuticals (ENTA)

Read MoreHide Full Article

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Enanta Pharmaceuticals (ENTA - Free Report) , which belongs to the Zacks Medical - Drugs industry, could be a great candidate to consider.

When looking at the last two reports, this biotechnology company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 11.52%, on average, in the last two quarters.

For the last reported quarter, Enanta Pharmaceuticals came out with earnings of $0.97 per share versus the Zacks Consensus Estimate of $0.96 per share, representing a surprise of 1.04%. For the previous quarter, the company was expected to post earnings of $0.50 per share and it actually produced earnings of $0.61 per share, delivering a surprise of 22%.

Price and EPS Surprise

For Enanta Pharmaceuticals, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Enanta Pharmaceuticals has an Earnings ESP of +7.26% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on November 26, 2018.

Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.

Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Enanta Pharmaceuticals, Inc. (ENTA) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in